Search

Your search keyword '"Manges, Robert F."' showing total 10 results
Start Over Author "Manges, Robert F."
10 results on '"Manges, Robert F."'

1. Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial

Author

Nowakowski, Grzegorz S., Willenbacher, Wolfgang, Greil, Richard, Larsen, Thomas S., Patel, Krish, Jäger, Ulrich, Manges, Robert F., Trümper, Lorenz, Everaus, Hele, Kalakonda, Nagesh, Brown, Peter, Jørgensen, Judit Meszaros, Cunningham, David, Dell’Aringa, Justine, Fox, Brian, Rubio, Neus Domper, Kilavuz, Nurgul, Casadebaig, Marie-Laure, Manzke, Oliver, and Munoz, Javier

Published
2022
Full Text
View/download PDF

2. Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL:a phase 2, open-label trial

Author

Nowakowski, Grzegorz S., Willenbacher, Wolfgang, Greil, Richard, Larsen, Thomas S., Patel, Krish, Jäger, Ulrich, Manges, Robert F., Trümper, Lorenz, Everaus, Hele, Kalakonda, Nagesh, Brown, Peter, Jørgensen, Judit Meszaros, Cunningham, David, Dell’Aringa, Justine, Fox, Brian, Rubio, Neus Domper, Kilavuz, Nurgul, Casadebaig, Marie Laure, Manzke, Oliver, Munoz, Javier, Nowakowski, Grzegorz S., Willenbacher, Wolfgang, Greil, Richard, Larsen, Thomas S., Patel, Krish, Jäger, Ulrich, Manges, Robert F., Trümper, Lorenz, Everaus, Hele, Kalakonda, Nagesh, Brown, Peter, Jørgensen, Judit Meszaros, Cunningham, David, Dell’Aringa, Justine, Fox, Brian, Rubio, Neus Domper, Kilavuz, Nurgul, Casadebaig, Marie Laure, Manzke, Oliver, and Munoz, Javier

Abstract

Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune checkpoint blockade can increase antitumor efficacy. This study investigated durvalumab, a programmed death-ligand 1 inhibitor, combined with R-CHOP or lenalidomide + R-CHOP (R2-CHOP) in newly diagnosed high-risk DLBCL. Patients received durvalumab 1125 mg every 21 days for 2–8 cycles + R-CHOP (non-activated B-cell [ABC] subtype) or R2-CHOP (ABC), then durvalumab consolidation (1500 mg every 28 days). Of 46 patients, 43 received R-CHOP and three R2-CHOP. All patients had the high-risk disease; 14 (30.4%) and eight (17.4%) had double- or triple-hit DLBCL, respectively. Following induction, 20/37 (54.1%) patients receiving durvalumab + R-CHOP achieved complete response (CR), and seven (18.9%) partial response (PR); 25 (67.6% [95% CI 50.2–82.0]) continued to consolidation and were progression-free at 12 months. Among efficacy-evaluable patients with double- or triple-hit DLBCL (n = 12), five achieved CR and five PR. Adverse events were generally consistent with R-CHOP. Correlative analyses did not identify conclusive biomarkers of response. Durvalumab + R-CHOP is feasible in DLBCL with no new safety signals, but the combination provided no greater benefit than R-CHOP.

Published
2022

3. Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial

Author

Nowakowski, Grzegorz S., primary, Willenbacher, Wolfgang, additional, Greil, Richard, additional, Larsen, Thomas S., additional, Patel, Krish, additional, Jäger, Ulrich, additional, Manges, Robert F., additional, Trümper, Lorenz, additional, Everaus, Hele, additional, Kalakonda, Nagesh, additional, Brown, Peter, additional, Jørgensen, Judit Meszaros, additional, Cunningham, David, additional, Dell’Aringa, Justine, additional, Fox, Brian, additional, Rubio, Neus Domper, additional, Kilavuz, Nurgul, additional, Casadebaig, Marie-Laure, additional, Manzke, Oliver, additional, and Munoz, Javier, additional

Published
2021
Full Text
View/download PDF

4. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

Author

Voorhees, Peter M., Manges, Robert F., Sonneveld, Pieter, Jagannath, Sundar, Somlo, George, Krishnan, Amrita, Lentzsch, Suzanne, Frank, Richard C., Zweegman, Sonja, Wijermans, Pierre W., Orlowski, Robert Z., Kranenburg, Britte, Hall, Brett, Casneuf, Tineke, Qin, Xiang, van de Velde, Helgi, Xie, Hong, and Thomas, Sheeba K.

Published
2013
Full Text
View/download PDF

5. Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.

Author

Nowakowski, Grzegorz S., Willenbacher, Wolfgang, Greil, Richard, Larsen, Thomas S., Patel, Krish, Jäger, Ulrich, Manges, Robert F., Trümper, Lorenz, Everaus, Hele, Kalakonda, Nagesh, Brown, Peter, Jørgensen, Judit Meszaros, Cunningham, David, Dell'Aringa, Justine, Fox, Brian, Rubio, Neus Domper, Kilavuz, Nurgul, Casadebaig, Marie-Laure, Manzke, Oliver, and Munoz, Javier

Abstract

Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune checkpoint blockade can increase antitumor efficacy. This study investigated durvalumab, a programmed death-ligand 1 inhibitor, combined with R-CHOP or lenalidomide + R-CHOP (R2-CHOP) in newly diagnosed high-risk DLBCL. Patients received durvalumab 1125 mg every 21 days for 2–8 cycles + R-CHOP (non-activated B-cell [ABC] subtype) or R2-CHOP (ABC), then durvalumab consolidation (1500 mg every 28 days). Of 46 patients, 43 received R-CHOP and three R2-CHOP. All patients had the high-risk disease; 14 (30.4%) and eight (17.4%) had double- or triple-hit DLBCL, respectively. Following induction, 20/37 (54.1%) patients receiving durvalumab + R-CHOP achieved complete response (CR), and seven (18.9%) partial response (PR); 25 (67.6% [95% CI 50.2–82.0]) continued to consolidation and were progression-free at 12 months. Among efficacy-evaluable patients with double- or triple-hit DLBCL (n = 12), five achieved CR and five PR. Adverse events were generally consistent with R-CHOP. Correlative analyses did not identify conclusive biomarkers of response. Durvalumab + R-CHOP is feasible in DLBCL with no new safety signals, but the combination provided no greater benefit than R-CHOP. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

6. Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL.

Author

Nowakowski, Grzegorz S., primary, Willenbacher, Wolfgang, additional, Greil, Richard, additional, Larsen, Thomas Stauffer, additional, Patel, Krish, additional, Jäger, Ulrich, additional, Manges, Robert F., additional, Trumper, Lorenz H., additional, Haioun, Corinne, additional, Everaus, Hele, additional, Kalakonda, Nagesh, additional, Knoble, Jeanna, additional, Brown, Peter, additional, Joergensen, Judit Meszaros, additional, Cunningham, David, additional, Domper, Neus, additional, Casadebaig, Marie-Laure, additional, Manzke, Oliver, additional, and Munoz, Javier, additional

Published
2019
Full Text
View/download PDF

7. A Phase 2 Multicenter Study of Siltuximab, An Anti-IL-6 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma,

Author

Voorhees, Peter M., primary, Manges, Robert F, additional, Sonneveld, Pieter, additional, Jagannath, Sundar, additional, Somlo, George, additional, Krishnan, Amrita, additional, Lentzsch, Suzanne, additional, Frank, Richard C, additional, Zweegman, Sonja, additional, Wijermans, P.W., additional, Rijnbeek, Britte, additional, Qin, Xiang, additional, Cornfeld, Mark J., additional, Xie, Hong, additional, and Thomas, Sheeba K., additional

Published
2011
Full Text
View/download PDF

8. Phase 3b UPFRONT Study: Interim Results From a Community Practice-Based Prospective Randomized Trial Evaluating Three Bortezomib-Based Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients.

Author

Niesvizky, Ruben, primary, Reeves, James, additional, Flinn, Ian W, additional, Rifkin, Robert M., additional, Clowney, Billy, additional, Gabrail, Nashat, additional, Phooshkooru, Vijay R., additional, Charu, Veena, additional, Chay, Christopher H., additional, Corzo, Deyanira, additional, Neuwirth, Rachel, additional, Manges, Robert F., additional, and Warr, Thomas A., additional

Published
2009
Full Text
View/download PDF

9. Preliminary Results of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody, in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma

Author

Rossi, Jean-Francois, primary, Manges, Robert F., additional, Sutherland, Heather J., additional, Jagannath, Sundar, additional, Voorhees, Peter, additional, Sonneveld, Pieter, additional, Delforge, Michel, additional, Pegourie, Brigitte, additional, Alegre, Adrian, additional, de la Rubia, Javier, additional, La Police, David, additional, Bandekar, Rajesh, additional, Xie, Hong, additional, and Orlowski, Robert Z., additional

Published
2008
Full Text
View/download PDF

10. Preliminary Results of CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb), in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma.

Author

Manges, Robert F., primary, Sutherland, Heather J., additional, Jagannath, Sundar, additional, Orlowski, Robert Z., additional, La Police, David, additional, DeWitte, Mark, additional, Lang, Zhihui, additional, Corringham, Robert E., additional, and Rossi, Jean Francois, additional

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results